Pascal D. Fortin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pascal D. Fortin has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
Cary Fridrich
47 shared publications- Alessandro A. Boezio
Relay Therapeutics, 60 Hampshire Street, Cambridge, Massachusetts 02139, United States
46 shared publications - Alexandre Larivée
10Paraza Pharma, Inc. Montreal, Canada
46 shared publications - Amanda Iskandar
Relay Therapeutics, Inc., Cambridge, Massachusetts
46 shared publications - Bret R. Williams
Relay Therapeutics, Inc., Cambridge, Massachusetts
46 shared publications - D. Randal Kipp
Relay Therapeutics, Inc., Cambridge, Massachusetts
46 shared publications
Latest Publications
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Isoform selectivity of RLY-2608
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Isoform selectivity of RLY-2608
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
In vitro kinome profile of RLY-2608. RLY-2608 was tested at a concentration of 10 µM by SelectScreen (ThermoFisher Scientific)
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Binding kinetics and potency of [2] towards PI3Kα
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Binding kinetics and potency of [2] towards PI3Kα
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Varied levels of PI3Kα-dependency across cell lines
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Varied levels of PI3Kα-dependency across cell lines
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
RLY-2608 biochemical inhibition with liposome substrates
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
RLY-2608 biochemical inhibition with liposome substrates
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Time-dependence of biochemical inhibition and mutant selectivity of RLY-2608
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Time-dependence of biochemical inhibition and mutant selectivity of RLY-2608
- Open Access
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608
- 8 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
Body weight changes observed in in vivo models upon treatment with RLY-2608